An interventional study of surgery and sacral neuromodulation in Spinal Vascular Disorder Nos and Overactive Bladder, sponsored by Xuanwu Hospital, Beijing. Status unknown. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2020-04-29.
Sponsored by Xuanwu Hospital, Beijing · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies testing tolterodine in Urinary Bladder, Overactive — 3 open to participants now, 3 under way, 1 of them phase 3. tolterodine · Urinary Bladder, Overactive.
Among the 30 studies testing tolterodine in Urinary Bladder, Overactive, this one is the 14th largest by planned enrollment of the 29 interventional ones that give a count, is one of 2 that started in 2023, is one of 2 with no phase, and was the 25th registered.
861 studies on the registry are indexed under Urinary Bladder, Overactive; 128 are open to participants now.
Browse Urinary Bladder, Overactive studies →3 of the 30 studies testing tolterodine in Urinary Bladder, Overactive are open now, in 2 countries. Recruiting first, the newest first:
Far Eastern Memorial Hospital · Sites in Taiwan
Ages 20+ · Women only
University of California, San Francisco · Sites in United States
Ages 60+ · Women only · Healthy volunteers
Far Eastern Memorial Hospital · Sites in Taiwan
Ages 18+ · Women only
By country, each count listing its studies:
tolterodine: first FDA approval 1998 (DETROL). What it is approved for, and how studies give it, is on its page →
Of the 75 Urinary Bladder, Overactive studies recruiting now, 45 (60%) set no upper age limit and 16 (21%) stop at 75 or younger; 7 take children under 18; 8 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 4 · Phase 3 4 · Phase 4 15
First in 2003; this study’s year is marked. 2 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is above the median of 70 across 651 interventional studies indexed under Urinary Bladder, Overactive.
Median enrollment 100 across the 29 interventional studies. Of the 24 that completed or were terminated, 8 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 30 have an industry lead sponsor. The 10 most frequent:
Xuanwu Hospital, Beijing is the lead sponsor of 365 studies on the registry; 231 are open to participants now.
Xuanwu Hospital, Beijing has 1 study filed under Urinary Bladder, Overactive — fewer than ten, so there is no comparison to draw.
1 of the studies testing tolterodine in Urinary Bladder, Overactive that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05362292University of California, San FranciscoTReating Incontinence for Underlying Mental and Physical Health | 2027-05-02 |
Add it to your calendar (.ics) → With an account.
Among the 30 studies testing tolterodine in Urinary Bladder, Overactive, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The investigators' goal is to compare the efficacy of three different management strategies (sacral neuromodulation, botulinum toxin, M receptor antagonist) in treating consistent OAB in patients with SVMs after surgery.
Spinal Vascular malformations (SVMs) are complex neurosurgical lesions and account for 3%-4% of all intradural spinal cord mass lesions, which can influence the function of bladder. The investigators' goal is to compare the efficacy of three different management strategies (sacral neuromodulation, botulinum toxin, M receptor antagonist) in treating consistent OAB (Overactive Bladder) in patients with SVMs after surgery.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
•Patient diagnosed with spinal vascular diseases including Intradural arteriovenous malformation,Intradural arteriovenous fistula,Dural arteriovenous fistula,Extradural arteriovenous malformation,Paravertebral arteriovenous malformation,Paravertebral arteriovenous fistula,cobbs' syndrome,and other spinal arteriovenous metameric syndromes involve the spinal cord.
Exclusion Criteria:
•patient received surgical treatment or interventional treatment before
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
patients with SVMs are of consistent OAB (Overactive Bladder) after surgery and undergo sacral neuromodulation (SNM)
Procedure: surgery · Procedure: sacral neuromodulation
patients with SVMs are of consistent OAB after surgery and accept botulinum toxin A (BTXA) injection
Procedure: surgery · Procedure: botulinum toxin A injection
patients with SVMs are of consistent OAB (Overactive Bladder) after surgery and accept M receptor antagonist
Procedure: surgery · Drug: M receptor antagonist
patients with SVMs receive surgery
sacral neuromodulation (SNM) with InterStimTM
BOTOX
Tolterodine
Also known as: Tolterodine
bladder function
bladder function change in urodynamics
Time frame: 3 months and 12 months
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Jan 2023; primary completion for Oct 2023, 9 months later.
Of 134 non-industry interventional studies with no phase under Urinary Bladder, Overactive, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 40. This study's planned 9 months is below that.
Counting every sponsor, half of 175 studies reached it within 19 months; a quarter within 10 and three quarters within 40.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tolterodine